Skip to content

HUB Organoids

services
technology
company
- about us
- careers
- events
- latest news
resources
license program
contact

Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR × LGR5 bispecific antibody with efficacy in epithelial tumors

Nat Cancer | April 2022

Contact Careers Privacy Policy

HUB Organoids is now part of the Life Science Business of Merck KGaA, Darmstadt, Germany

X

Have any questions?

contact us